TY - JOUR
T1 - Developing a digital solution for remote assessment in multiple sclerosis
T2 - From concept to software as a medical device
AU - van der Walt, Anneke
AU - Butzkueven, Helmut
AU - Shin, Robert K.
AU - Midaglia, Luciana
AU - Capezzuto, Luca
AU - Lindemann, Michael
AU - Davies, Geraint
AU - Butler, Lesley M.
AU - Costantino, Cristina
AU - Montalban, Xavier
N1 - Funding Information:
Conflicts of Interest: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.v.d.W. received travel support, speaker honoraria and served on advisory boards for Biogen, Merck, Genzyme, Novartis and Teva. H.B. has received institutional (Monash University) funding from Biogen, F. Hoffmann-La Roche Ltd., Merck and Novartis; has carried out contracted research for Novartis, Merck, F. Hoffmann-La Roche Ltd. and Biogen; has taken part in speakers’ bureaus for Biogen, Genzyme, F. Hoffmann-La Roche Ltd. and Merck; has received personal grants from Oxford PharmaGenesis and Biogen (prior to 30 June 2018). R.K.S. has received consulting fees and speaker honoraria from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis and Sanofi Genzyme. L.M. has nothing to disclose. L.C. is an employee of F. Hoffmann-La Roche Ltd. M.L. is a consultant for F. Hoffmann-La Roche Ltd. via Inovigate. G.D. is an employee of F. Hoffmann-La Roche Ltd. L.M.B. is an employee of F. Hoffmann-La Roche Ltd. C.C. is an employee and shareholder of F. Hoffmann-La Roche Ltd. X.M. has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials, and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb/Celgene, EMD Serono, Genzyme, F. Hoffmann-La Roche Ltd., Immunic Therapeutics, Janssen Pharmaceuticals, MedDay, Merck, Mylan, NervGen Pharma Corp., Novartis, Sanofi Genzyme, Teva Pharmaceuticals, TG Therapeutics, EXCEMED, Multiple Sclerosis International Federation and National Multiple Sclerosis Society.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - There is increasing interest in the development and deployment of digital solutions to improve patient care and facilitate monitoring in medical practice, e.g., by remote observation of disease symptoms in the patients’ home environment. Digital health solutions today range from non-regulated wellness applications and research-grade exploratory instruments to regulated software as a medical device (SaMD). This paper discusses the considerations and complexities in developing innovative, effective, and validated SaMD for multiple sclerosis (MS). The development of SaMD requires a formalised approach (design control), inclusive of technical verification and analytical validation to ensure reliability. SaMD must be clinically evaluated, characterised for benefit and risk, and must conform to regulatory requirements associated with device classification. Cybersecurity and data privacy are also critical. Careful consideration of patient and provider needs throughout the design and testing process help developers overcome challenges of adoption in medical practice. Here, we explore the development pathway for SaMD in MS, leveraging experiences from the development of Floodlight™ MS, a continually evolving bundled solution of SaMD for remote functional assessment of MS. The development process will be charted while reflecting on common challenges in the digital space, with a view to providing insights for future developers.
AB - There is increasing interest in the development and deployment of digital solutions to improve patient care and facilitate monitoring in medical practice, e.g., by remote observation of disease symptoms in the patients’ home environment. Digital health solutions today range from non-regulated wellness applications and research-grade exploratory instruments to regulated software as a medical device (SaMD). This paper discusses the considerations and complexities in developing innovative, effective, and validated SaMD for multiple sclerosis (MS). The development of SaMD requires a formalised approach (design control), inclusive of technical verification and analytical validation to ensure reliability. SaMD must be clinically evaluated, characterised for benefit and risk, and must conform to regulatory requirements associated with device classification. Cybersecurity and data privacy are also critical. Careful consideration of patient and provider needs throughout the design and testing process help developers overcome challenges of adoption in medical practice. Here, we explore the development pathway for SaMD in MS, leveraging experiences from the development of Floodlight™ MS, a continually evolving bundled solution of SaMD for remote functional assessment of MS. The development process will be charted while reflecting on common challenges in the digital space, with a view to providing insights for future developers.
KW - Clinical validation
KW - Digital health
KW - Digital health solution development
KW - Monitoring
KW - MS apps
KW - Multiple sclerosis
KW - Participatory health
KW - Smartphone-based assessments
KW - Software as a medical device
KW - Technical validation
UR - http://www.scopus.com/inward/record.url?scp=85115654465&partnerID=8YFLogxK
U2 - 10.3390/brainsci11091247
DO - 10.3390/brainsci11091247
M3 - Review Article
C2 - 34573267
AN - SCOPUS:85115654465
SN - 2076-3425
VL - 11
JO - Brain Sciences
JF - Brain Sciences
IS - 9
M1 - 1247
ER -